Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9436375 | 0.79 | RAB9A (0.49) | MAPTGLAAOC3 | |
| SCHEMBL27616039 | 0.78 | KMT2A (0.56) | ESR1ESR2USP7MAPTADORA2A | |
| SCHEMBL27635292 | 0.78 | HTR2B (0.46) | MAPTADORA2AADORA1 | |
| Bromide SCHEMBL9195420 | 0.77 | RAB9A (0.47) | MAPTGLAAOC3 | |
| SCHEMBL3894243 | 0.76 | ADORA2A (0.37) | MAPTADORA2AADORA1AOC3 | |
| SCHEMBL10190451 | 0.67 | ESR2 (0.56) | ESR1ESR2USP7 | |
| SCHEMBL3976477 | 0.65 | KMT2A (0.48) | ESR1ESR2USP7MAPT | |
| SCHEMBL17016701 | 0.65 | SLC2A1 (0.49) | MAPT | |
| SCHEMBL4138997 | 0.64 | KDM4E (0.58) | APPMAPTAOC3 | |
| SCHEMBL28204878 | 0.64 | ESR2 (0.52) | ESR1ESR2USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1688549-A | Compound having TGF-beta inhibitory activity and medicinal composition containing the same | KIRIN BREWERY (JP) | 2005-10-26 | — | — | CN | disclosed |